AnnJi Pharmaceutical announced on the 22nd that its investigational drug AJ201 for the treatment of spinal and bulbar muscular atrophy (SBMA) has successfully achieved the primary endpoints of safety and tolerability in its Phase 1b/2a clinical trial. Additionally, multiple key clinical indicators demonstrated encouraging therapeutic effects and potential. RNA sequencing analysis confirmed that AJ201 activates the Nrf2-associated pathway.
The company stated that the study was a multi-center, randomized, double-blind, placebo-controlled clinical trial conducted at six clinical sites across the United States. The trial aimed to evaluate the safety and tolerability of AJ201 in SBMA patients, while also collecting data on pharmacokinetics, pharmacodynamics, and exploratory clinical endpoints. Although the trial was not designed to establish efficacy, the results provide positive signals and reference points for further development of AJ201 as a treatment for SBMA.
Dr. Christopher Grunseich, the lead principal investigator of the trial, commented, “This study has successfully achieved most of its predefined objectives, and the results are encouraging. AJ201 demonstrated positive clinical benefits, including improvements in functional assessments, favorable changes in serum biomarkers, and activation of the Nrf2 pathway as shown by RNA sequencing analysis. These findings further reinforce its therapeutic potential.”
Wendy Huang, Chairperson and CEO of AnnJi Pharmaceutical, stated, “SBMA is a slowly progressing neuromuscular disease for which there is currently no effective treatment. We are greatly encouraged by the clinically meaningful positive responses observed within a short treatment period. These preliminary results strengthen our confidence in AJ201. We are committed to advancing this program into a Phase 3 clinical trial and actively seeking development and commercial partners, with the hope of delivering the first safe and effective treatment option for SBMA patients.”
Based on the results of this clinical trial, AnnJi plans to design the next Phase 2/3 trial. The company will promptly consult with the U.S. Food and Drug Administration (FDA) and simultaneously engage in discussions with domestic and international pharmaceutical companies for potential co-development or licensing partnerships.
Resource: 安基罕病新藥臨床1b/2a試驗結果亮眼 顯示正向治療潛力
